Navigation Links
Aeras and China National Biotech Group Sign Memorandum of Understanding for TB Vaccine R&D Collaboration
Date:7/25/2011

ROCKVILLE, Md. and BEIJING, July 26, 2011 /PRNewswire-USNewswire/ -- Aeras and the China National Biotech Group (CNBG) today announced the signing of a memorandum of understanding for the organizations to pursue opportunities to jointly develop tuberculosis (TB) vaccines in China and potentially other parts of the world.

The partnership is intended to leverage both organizations' capabilities to support the development of TB vaccines.  TB is a major public health priority in China, where there are more than one million new TB cases every year.  The scope of potential activities will cover the full spectrum of product development, including pre-clinical development, process development and manufacturing, and clinical development in TB and potentially other disease areas.  Details of the specific activities and areas of focus of the collaboration will be set forth in a future definitive agreement.

"Aeras is excited to expand our relationship with CNBG," said Jim Connolly, President & Chief Executive Officer of Aeras. "The synergy created by bringing together CNBG's considerable infrastructure and manufacturing expertise with Aeras' promising TB vaccine pipeline, as well as our clinical and technical expertise, will significantly enhance the likelihood of a new TB vaccine being developed quickly and efficiently."

"At CNBG, we recognize the urgent need to combat tuberculosis and other infectious diseases in both China and around the world," said Xiaoming Yang, President of CNBG.  "This new collaboration will bring more opportunities to both organizations in pursuing greater innovation and building increased technical capacity for vaccine development."

The global TB epidemic is responsible for the deaths of 1.7 million people annually.  Co-infection with HIV/AIDS and the spread of drug-resistant forms of TB make it difficult to diagnose and treat, especially in poor and marginalized communities.  New to
'/>"/>

SOURCE Aeras
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Aeras, Crucell and South African Tuberculosis Vaccine Initiative Announce Encouraging Preliminary Results of Tuberculosis Vaccine Clinical Trial in South Africa
2. Aeras Global TB Vaccine Foundation Announces Appointment of Accomplished Pharmaceutical Executive as President and CEO
3. HUYA Bioscience Intl Announces Clinical Trial Milestones in China for Promising New Anti-Arrhythmic Compound; Data Supports Desirable Safety Profile
4. HUYA Bioscience Intl Announces World-Class Clinical Advisory Team for New Anti-Arrhythmic Compound Sourced From China
5. HUYA Bioscience Intl Announces First Pre-IND Outcome for a Development Stage Compound Sourced From China - HBI-8000, Promising New Cancer Compound
6. HUYA Bioscience Intl Announces Pre-IND Outcome for HBI-3000 - Promising Anti-Arrhythmia Compound Sourced From China
7. China Sky One Medical, Inc. Announces 26 New Drugs in Clinical Trials
8. RHEI Pharmaceuticals Announces the Initiation of the Final Clinical Study for Approval of Tibozole in China
9. Varian Medical Systems to Exhibit Cancer Treatment and X-ray Imaging Technologies at China Med Exhibition
10. China Sky One Medical, Inc. Achieves Significant Breakthrough in Research for Sudden Cardiac Death (SCD) Early Examination Kit
11. China Animal Welfare Law Under Review While 36,000 Dogs Culled
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... -- A new report by the Global ... people across 13 countries bring an end to open ... latest Progress Report details how its financial support for ... 20,500 communities become open-defecation free, improved toilets for 4.2 ... to hand-washing facilities. The Progress Report highlights ...
(Date:6/2/2015)... und MADRID ... Mündliche Präsentation (Abstract   10503), ... of Clinical Oncology    PharmaMar ... LLC ( Janssen) Daten der multizentrischen ... signifikante Verbesserung beim progressionsfreien Überleben (progression-free survival, ...
(Date:6/1/2015)... THOUSAND OAKS, Calif. , June 2, 2015 ... announced a collaboration with Roche on a Phase ... of talimogene laherparepvec, Amgen,s investigational oncolytic immunotherapy, in ... known as MPDL3280A), in patients with triple-negative breast ... Talimogene laherparepvec is an investigational oncolytic immunotherapy ...
Breaking Medicine Technology:Global Sanitation Fund Reports Major Sanitation & Hygiene Advances for Seven Million People in 13 Countries 2PharmaMar gibt bekannt, Janssens Studie zeige, dass Trabectedin die Krankheitsbekämpfung bei Patienten mit fortgeschrittenem Weichgewebesarkom verbessert 2PharmaMar gibt bekannt, Janssens Studie zeige, dass Trabectedin die Krankheitsbekämpfung bei Patienten mit fortgeschrittenem Weichgewebesarkom verbessert 3PharmaMar gibt bekannt, Janssens Studie zeige, dass Trabectedin die Krankheitsbekämpfung bei Patienten mit fortgeschrittenem Weichgewebesarkom verbessert 4PharmaMar gibt bekannt, Janssens Studie zeige, dass Trabectedin die Krankheitsbekämpfung bei Patienten mit fortgeschrittenem Weichgewebesarkom verbessert 5PharmaMar gibt bekannt, Janssens Studie zeige, dass Trabectedin die Krankheitsbekämpfung bei Patienten mit fortgeschrittenem Weichgewebesarkom verbessert 6Amgen Announces Collaboration With Roche On Cancer Immunotherapy Study With Investigational Medicines Talimogene Laherparepvec And Atezolizumab 2Amgen Announces Collaboration With Roche On Cancer Immunotherapy Study With Investigational Medicines Talimogene Laherparepvec And Atezolizumab 3Amgen Announces Collaboration With Roche On Cancer Immunotherapy Study With Investigational Medicines Talimogene Laherparepvec And Atezolizumab 4Amgen Announces Collaboration With Roche On Cancer Immunotherapy Study With Investigational Medicines Talimogene Laherparepvec And Atezolizumab 5Amgen Announces Collaboration With Roche On Cancer Immunotherapy Study With Investigational Medicines Talimogene Laherparepvec And Atezolizumab 6Amgen Announces Collaboration With Roche On Cancer Immunotherapy Study With Investigational Medicines Talimogene Laherparepvec And Atezolizumab 7
... Oct. 21 , Higher volume drives revenue growth ... $.86 (reported) or $1.20 (pro forma non-GAAP) Full-year 2009 EPS guidance range ... , Eli Lilly and Company (NYSE: LLY ) today announced financial results for ... data Third Quarter, ...
... IRIDEX Corporation (Nasdaq: IRIX ) today announced ... solution, which will be featured at the ... San Francisco. , "Our new Modular Multi-Wavelength ... photocoagulator market segment with a flexible, reliable, and ...
Cached Medicine Technology:Lilly Reports Solid Third-Quarter 2009 Results; Revises Full-Year 2009 EPS Guidance 2Lilly Reports Solid Third-Quarter 2009 Results; Revises Full-Year 2009 EPS Guidance 3Lilly Reports Solid Third-Quarter 2009 Results; Revises Full-Year 2009 EPS Guidance 4Lilly Reports Solid Third-Quarter 2009 Results; Revises Full-Year 2009 EPS Guidance 5Lilly Reports Solid Third-Quarter 2009 Results; Revises Full-Year 2009 EPS Guidance 6Lilly Reports Solid Third-Quarter 2009 Results; Revises Full-Year 2009 EPS Guidance 7Lilly Reports Solid Third-Quarter 2009 Results; Revises Full-Year 2009 EPS Guidance 8Lilly Reports Solid Third-Quarter 2009 Results; Revises Full-Year 2009 EPS Guidance 9Lilly Reports Solid Third-Quarter 2009 Results; Revises Full-Year 2009 EPS Guidance 10Lilly Reports Solid Third-Quarter 2009 Results; Revises Full-Year 2009 EPS Guidance 11Lilly Reports Solid Third-Quarter 2009 Results; Revises Full-Year 2009 EPS Guidance 12Lilly Reports Solid Third-Quarter 2009 Results; Revises Full-Year 2009 EPS Guidance 13Lilly Reports Solid Third-Quarter 2009 Results; Revises Full-Year 2009 EPS Guidance 14Lilly Reports Solid Third-Quarter 2009 Results; Revises Full-Year 2009 EPS Guidance 15Lilly Reports Solid Third-Quarter 2009 Results; Revises Full-Year 2009 EPS Guidance 16Lilly Reports Solid Third-Quarter 2009 Results; Revises Full-Year 2009 EPS Guidance 17Lilly Reports Solid Third-Quarter 2009 Results; Revises Full-Year 2009 EPS Guidance 18Lilly Reports Solid Third-Quarter 2009 Results; Revises Full-Year 2009 EPS Guidance 19Lilly Reports Solid Third-Quarter 2009 Results; Revises Full-Year 2009 EPS Guidance 20Lilly Reports Solid Third-Quarter 2009 Results; Revises Full-Year 2009 EPS Guidance 21IRIDEX Introduces Modular Multi-Wavelength Laser Solution at the American Academy of Ophthalmology 2
(Date:6/2/2015)... 02, 2015 The Radiosurgery Society® ... from the RSSearch® Patient Registry evaluating the treatment ... (SBRT) for the treatment of centrally located primary ... , The study, published in the May, ... included 111 patients with 114 centrally located lung ...
(Date:6/2/2015)... Colorado (PRWEB) June 02, 2015 ... Chief Medical Officer at the Steadman Philippon Research Institute, ... Too Early for Single Sport Specialization? ” This was ... Sports Medicine (AOSSM) Research Committee that was recently published ... data for this project was limited, there is evidence ...
(Date:6/2/2015)... (PRWEB) June 02, 2015 Each year, ... Insiders’ Choice Beauty Awards. This year, the organization’s members ... the winner of the QVC® Beauty Quest Award at ... results-driven Micro Emulsion (ME) Technology and 2-in-1 approach to ... Also noting the brand’s loyal consumer and professional fan ...
(Date:6/2/2015)... View, CA (PRWEB) June 02, 2015 ... mandated vaccination schedule for children to attend public or ... Judiciary and Education but bypassed the Appropriations Committee (Sacramento ... floor 25-10 despite contentious hearings. , “We believe ... Personal Belief Exemptions (PBEs) more than it will (the) ...
(Date:6/1/2015)... June 02, 2015 The National ... Wirski as a 2015-2016 inductee into its VIP ... this prestigious distinction for leadership in business. NAPW is ... boasting more than 700,000 members and over 200 operating ... this prestigious honor,” said NAPW President Star Jones. “Job ...
Breaking Medicine News(10 mins):Health News:New Study from RSSearch® Patient Registry Highlights Treatment Patterns and Clinical Outcomes of Stereotactic Radiosurgery for Central Lung Tumors 2Health News:New Study from RSSearch® Patient Registry Highlights Treatment Patterns and Clinical Outcomes of Stereotactic Radiosurgery for Central Lung Tumors 3Health News:Early Single Sport Specialization May Put Youth Athletes at Risk for Overuse Injuries According to Colorado Knee Specialist Robert LaPrade, MD, PhD 2Health News:Early Single Sport Specialization May Put Youth Athletes at Risk for Overuse Injuries According to Colorado Knee Specialist Robert LaPrade, MD, PhD 3Health News:Scalisi Skincare Wins Coveted CEW QVC Beauty Quest Award for Innovative and Patented Formulation 2Health News:A Voice For Choice Releases A Statement As SB277 Is Referred To Single Assembly Committee And Bypasses Education and Judicial Scrutiny 2Health News:National Association of Professional Women Inducts Miriam Wirski, Holistic Life Coach, Into its VIP Woman of the Year Circle 2
... Data that shed new light on,the treatment of ... immune thrombocytopenic purpura, and venous,thrombosis in relation to ... 49th Annual Meeting of the American Society of,Hematology ... this new research,on Saturday, December 8, from 10:00 ...
... is a clear link between GABA a chemical ... in the brain and nicotine dependence, according ... of Neuropsychopharmacology (ACNP) annual meeting. Researchers discovered that nicotine ... could potentially help curb the pleasurable effects of nicotine ...
... link between mitochondria, memory and socialization , FRIDAY, ... respiration deficiencies in mitochondria (the source of energy ... behavior and spatial memory, Japanese researchers report. , ... link between mitochondrial malfunction and mental illness in ...
... more invasive treatment is necessary, researchers say , , FRIDAY, Dec. 7 ... test to detect lung cancer, according to a Duke University Medical ... Dec. 10 issue of the Journal of Clinical Oncology , ... RBP, SCC and AAT -- may provide a simple follow-up for ...
... that we must remain vigilant,in protecting women,s access to ... care professionals who provide that care, WASHINGTON, Dec. ... President and CEO of the National Abortion,Federation, on the ... Albuquerque,NM:, As the professional association of abortion providers, ...
... KING OF PRUSSIA, Pa., Dec. 7 Universal ... that its Board of Directors,authorized an additional 5 ... shares remaining under previously announced authorizations.,Pursuant to the ... time as,conditions allow, may purchase shares on the ...
Cached Medicine News:Health News:Research Highlights New Approaches to Management of Blood Clotting and Bleeding Disorders 2Health News:Research Highlights New Approaches to Management of Blood Clotting and Bleeding Disorders 3Health News:Research Highlights New Approaches to Management of Blood Clotting and Bleeding Disorders 4Health News:Research Highlights New Approaches to Management of Blood Clotting and Bleeding Disorders 5Health News:Research Highlights New Approaches to Management of Blood Clotting and Bleeding Disorders 6Health News:Study suggests nicotine addiction might be controlled by influencing brain mechanisms 2Health News:Blood Test to Detect Lung Cancer Being Eyed 2
... Savant offers several different two-stage, oil-sealed, rotary ... freeze drying applications. Each pump comes complete ... Kit) and and Oil Mist Filter (EMF-10). ... full gas ballast to keep the oil ...
Produces vacuum pressures required for 96 well kits...
Inquire...
... The Perfect Single Vac ... one 96-well plate in 30 ... with an "open/closed" switch and ... for easy operation. contains vacuum ...
Medicine Products: